This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also keep up to date by following us on Twitter or LinkedIn  


DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES

DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES Former Novartis executive to lead emerging biotech with a novel precision approach to autoimmune disease, supported by recent senior appointments MiroBio is exclusively focused on checkpoint agonists produced by its unique discovery engine that comprehensively maps inhibitory checkpoint signaling pathways Clinical initiation with... Read more

Exscientia in $70M collaboration for anti-virals against coronavirus & other pandemic potential viruses

Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches — Exscientia to use leading AI platform and in-house drug expertise to discover and develop five phase 1-ready... Read more

MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200

Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform Oxford 10th August 2021; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 trial of OVM-200 has been received from the MHRA (Medicines and Healthcare products... Read more

Significant expansion of AI firm Exscientia’s headquarters at TOSP

Significant expansion of AI firm Exscientia’s headquarters at TOSP Job creation to continue beyond 100 roles added already this year Oxford, UK, August 4 2021 – Exscientia, the clinical stage, artificial intelligence-driven pharmatech company, has announced a significant expansion of its headquarters at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies. The company, which initially occupied c... Read more

Sensyne Health – Appointment of Chief Scientific Officer

Dr. David Ruau joins Sensyne Health from Bayer Pharmaceuticals Oxford, U.K. 22 July 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the ethical AI company, today announces the appointment of Dr David Ruau to the newly created role of Chief Scientific Officer with effect from 01 September 2021. In this role, David will lead the research effort at Sensyne aimed at applying ethical AI to the improvement of patient care and... Read more